Top

Clinical Drug Investigation

Published in:

01-05-2009 | Original Research Article

Combination Therapy with Candesartan Cilexetil 32mg and Hydrochlorothiazide 25mg Provides the Full Additive Antihypertensive Effect of the Components

A Randomized, Double-Blind, Parallel-Group Study in Primary Care

Author: Prof Istvan Edes

Published in: Clinical Drug Investigation | Issue 5/2009

Abstract

Background and objective: Fixed-combination tablets of candesartan (orally administered as the pro-drug candesartan cilexetil and hereafter referred to as candesartan) and hydrochlorothiazide (HCTZ) 8/12.5mg and 16/12.5mg are effective and well tolerated. However, some patients require higher doses to attain target blood pressure, and combination tablets containing candesartan and HCTZ at the upper end of their respective dose ranges are now being developed. This study aimed to assess the antihypertensive effect and tolerability of the combination of candesartan 32mg and HCTZ 25mg versus candesartan 32mg monotherapy, HCTZ 25mg monotherapy, and placebo.

Methods: This was a randomized, double-blind, parallel-group study, with 8 weeks of follow-up, carried out in primary-care outpatients. 1524 men or women (age 20–80 years) with mild to moderate primary hypertension and sitting diastolic blood pressure (DBP) 90–114 mmHg after 4 weeks’ single-blind placebo treatment were included in the study. Candesartan/ HCTZ 32/25mg combination therapy, candesartan 32mg monotherapy, HCTZ 25mg monotherapy, and placebo, allocated in a 5: 5: 5: 1 ratio, were administered once daily. The main outcome measure was adjusted (analysis of covariance) mean reductions in systolic blood pressure (SBP) and DBP.

Results: Mean reductions in SBP and DBP were significantly greater with candesartan/HCTZ 32/25mg (21/14 mmHg) than with candesartan 32mg (13/9 mmHg), HCTZ 25mg (12/8 mmHg) or placebo (4/3 mmHg) [p <0.001 for all comparisons]. The proportion of patients with controlled blood pressure (SBP <140 mmHg and DBP <90 mmHg) at the end of the study was also significantly greater in the candesartan/HCTZ 32/25mg group (63%) than in the other treatment groups (p <0.001 for all comparisons). All study treatments were generally well tolerated.

Conclusion: The antihypertensive effect of candesartan/HCTZ 32/25mg represents fully additive contributions from each of its components, and is generally well tolerated in patients with mild to moderate primary hypertension. This combination adds to the treatment options for improving blood pressure control in patients with hypertension.

Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362(9395): 1527–35CrossRef

Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999 Feb; 17(2): 151–83

Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6): 1105–87PubMedCrossRef

Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003 May 21; 289(19): 2560–72PubMedCrossRef

Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 Jun 13; 351(9118): 1755–62PubMedCrossRef

Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62(8): 1253–87PubMedCrossRef

Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens 1999 Dec; 12 (12 Pt 1-2): 1181–7PubMedCrossRef

Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT₁-receptor blockers: differences in potency and efficacy. Blood Pressure 2002; 11(5): 293–301PubMedCrossRef

Ramsay LE, Yeo WW, Chadwick IG, et al. Diuretics. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell Scientific Publications, 1994

10.

Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996 Sep 30; 101Suppl. 3A: 71–82CrossRef

11.

Philipp T, Letzel H, Arens H-J. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997 Sep; (11 Suppl.) 2: 67-8

12.

Papademetriou V, Reif M, Henry D, et al. Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension. J Clin Hypertens 2000 Nov/Dec; 2(6): 372–8

13.

Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs 2002; 62(5): 787–816PubMedCrossRef

14.

Brewster LW, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004 Oct 19; 141(8): 614–27PubMed

15.

Bönner G, for the Multicentre Study Group. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5mg and 32/25mg in patients not optimally controlled with candesartan monotherapy. Blood Pressure 2008; 17Suppl. 2: 22–30CrossRef

16.

Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs 2006; 66(14): 1881–01PubMedCrossRef

17.

Fenton C, Keating GM, Scott LJ. Telmisartan/hydrochlorothiazide in the treatment of essential hypertension. Drugs 2003; 63(19): 2013–26PubMedCrossRef

18.

Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008 Apr; 22(4): 266–74PubMedCrossRef

19.

Gradman AH, Brady WE, Gazdick LP, et al. A multicentre, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100mg/hydrochlorothiazide 25mg and losartan 50mg/ hydrochlorothiazide 12.5mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002 Jul; 24(7): 1049–61PubMedCrossRef

20.

Bakris G, Gradman A, Reif M, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich) 2001 Jan–Feb; 3(1): 16–21CrossRef

21.

Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM study II. J Hum Hypertens 2001 Jul; 15(7): 475–80PubMedCrossRef

22.

Öhman KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension: comparison with a combination of losartan and hydrochlorothiazide. Blood Pressure 2000; 9(4): 214–20CrossRef

23.

Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: results of the CARLOS-study. Clin Drug Invest 2000 April; 19(4): 239–46CrossRef

Title: Combination Therapy with Candesartan Cilexetil 32mg and Hydrochlorothiazide 25mg Provides the Full Additive Antihypertensive Effect of the Components
A Randomized, Double-Blind, Parallel-Group Study in Primary Care
Author: Prof Istvan Edes
Publication date: 01-05-2009
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 5/2009
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200929050-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Combination Therapy with Candesartan Cilexetil 32mg and Hydrochlorothiazide 25mg Provides the Full Additive Antihypertensive Effect of the Components

A Randomized, Double-Blind, Parallel-Group Study in Primary Care

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4mg/day to Solifenacin Treatment

RETRACTED ARTICLE: Anti-Fracture Efficacy of Risedronic Acid in Men

Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain

HairMax LaserComb® Laser Phototherapy Device in the Treatment of Male Androgenetic Alopecia

Effect of Ivabradine, a Novel Antianginal Agent, on Driving Performance

Pharmacokinetics of Two 6-Day Frovatriptan Dosing Regimens Used for the Short-Term Prevention of Menstrual Migraine